Compare UPBD & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | SANA |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2021 |
| Metric | UPBD | SANA |
|---|---|---|
| Price | $17.94 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $32.25 | $7.50 |
| AVG Volume (30 Days) | 771.8K | ★ 1.9M |
| Earning Date | 05-22-2026 | 06-10-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $4,695,061,000.00 | N/A |
| Revenue This Year | $6.30 | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | $14.64 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $1.27 |
| 52 Week High | $28.03 | $6.55 |
| Indicator | UPBD | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 32.17 | 30.88 |
| Support Level | $17.18 | $2.85 |
| Resistance Level | $19.91 | $3.24 |
| Average True Range (ATR) | 0.88 | 0.25 |
| MACD | -0.44 | -0.08 |
| Stochastic Oscillator | 5.42 | 6.55 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.